So is it possible that Merck wants a smooth transition with NWBO. Sending over their guy. Could this also be a strategic move by Merck. IMO big pharma RULES!! Just a thought.
We have not seen what clinicans have seen. Anyone that crossed over due to pseudoprogression, started new DCVax-L regimen and then a checkpoint inhibitor may have seen complete remission and their clinician knows this. Why do you think Dr. Ashkan is sooo emphatic about getting this to patients not just ASAP but a whole bunch of yesterday's ago? My guess is a clinician's view makes a big difference but unfortunately not to "the process". Best wishes.
News 
Market Data 
Discover 
